The landscape of multiple myeloma treatment is rapidly advancing, with CELMoDs (Cereblon E3 Ligase Modulators) emerging as a next-generation therapy. While Revlimid has been a cornerstone in managing multiple myeloma, growing concerns over resistance and adverse effects have fueled the search for more effective alternatives. CELMoDs offer a promising solution, delivering enhanced efficacy and...